Overview
Mermaid diagram (expand to render)
Southeast Asia represents an emerging hub for biotechnology research and pharmaceutical development, with increasing focus on neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The region benefits from growing government support, expanding research infrastructure, and increasing private investment in healthcare and life sciences [1][2].
The ten ASEAN countries have varying levels of biotech development, with Singapore serving as the regional hub, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines have expanding pharmaceutical and biotech sectors with growing CNS research capabilities. The region's combined population of over 650 million people presents a significant patient pool for clinical development, while the diversity of genetic backgrounds offers unique research opportunities [3][4].
Regional Biotech Ecosystem
The Southeast Asian biotech ecosystem has evolved significantly over the past two decades, transitioning from primarily generic pharmaceutical manufacturing to innovative drug development. Several factors have contributed to this evolution [5][6]:
Government initiatives: National biotechnology strategies in Singapore, Malaysia, Thailand, and Indonesia have provided funding and policy support
Research infrastructure: Establishment of world-class universities and research institutes
Talent development: Investment in STEM education and research training
Foreign investment: Multinational pharmaceutical companies establishing R&D centers
Regional integration: ASEAN economic community facilitating cross-border collaborationMarket Opportunity
The neurodegenerative disease drug market in Southeast Asia represents a significant opportunity [7][8]:
- Aging population: Rapidly aging demographics in Singapore, Thailand, and Japan-increasing the prevalence of dementia
- Rising disease burden: Increasing incidence of Alzheimer's and Parkinson's in the region
- Healthcare expenditure: Growing healthcare spending and insurance coverage
- Unmet needs: Limited access to innovative therapies creates market opportunity
- Clinical advantages: Faster patient recruitment and lower trial costs
Country Profiles
Singapore
Singapore is the leading biotech hub in Southeast Asia with established companies developing treatments for neurodegenerative diseases. The city-state has positioned itself as "Biopolis" of Asia, attracting global pharmaceutical companies and fostering homegrown innovation [9][10].
Key Companies
- [Singapore/Asia-Pacific Neurodegeneration Biotech Companies](/companies/singapore-asia-pacific-neurodegeneration-biotech)
Key companies and their focus areas include:
ES Revive: Early-stage company developing neuroprotective compounds targeting mitochondrial dysfunction in Parkinson's disease. The company leverages proprietary screening platforms to identify small molecules that enhance neuronal survival [11].
Virometix: Focused on viral vector delivery systems for CNS gene therapy applications. Their technology enables targeted delivery of therapeutic genes to specific brain regions affected in Alzheimer's and Parkinson's [12].
Mirxes: Specializes in microRNA-based diagnostics and therapeutics for neurodegenerative diseases. Their lead program focuses on blood-based biomarkers for early detection of Alzheimer's disease [13].
Craytor Therapeutics: Developing small molecule inhibitors of tau aggregation, with a lead compound in preclinical development for Alzheimer's disease treatment [14].
Research Institutions
Singapore's research ecosystem includes several world-class institutions:
- National Neuroscience Institute (NNI): Premier research and clinical center for neurological disorders
- Agency for Science, Technology and Research (A*STAR): Government research agency with significant neuroscience programs
- Duke-NUS Medical School: Medical research university with neuroscience research focus
- Nanyang Technological University (NTU): Engineering and science research with neurotechnology programs
Government Support
The Singapore government has invested heavily in biotechnology through [15][16]:
- Biomedical Sciences Initiative: $6B+ investment in biomedical R&D
- Research, Innovation and Enterprise (RIE) Plan: Continuous funding for life sciences
- Tax incentives: R&D tax credits and exemptions for biotech companies
- Talent programs: Attraction and retention of international scientific talent
Thailand
Thailand has a growing pharmaceutical industry with several companies developing CNS and neurodegenerative disease treatments. The country combines strong manufacturing capabilities with expanding research capabilities [17][18].
Key Companies
- [Thailand Neurodegeneration Biotech Companies](/companies/thailand-neurodegeneration-biotech)
Key companies include:
BioNet-Asia: Leading Thai biotech focused on vaccine and immunotherapy development, with emerging interest in neuroinflammation approaches for neurodegenerative diseases [19].
Sripa Pharmaceuticals: Generic pharmaceutical company expanding into innovative CNS drug development, with partnerships with international biotech companies [20].
Greater Pharma: Established pharmaceutical company with CNS portfolio including treatments for movement disorders and cognitive impairment [21].
Government Pharmaceutical Organization (GPO): State-owned organization developing and manufacturing essential medicines, with interest in neurodegenerative disease treatments [22].
Research Capabilities
Thailand's research infrastructure includes:
- Chulalongkorn University: Medical school with strong neuroscience research programs
- Mahidol University: Leading research university with pharmacology and neuroscience departments
- Chiang Mai University: Northern Thailand research hub with natural products research
- Thailand Center of Excellence in Health: Government research funding body
Market Characteristics
Thailand's pharmaceutical market features [23][24]:
- Universal healthcare coverage: National health insurance scheme providing broad access
- Growing generics industry: Strong domestic generic manufacturing
- Clinical trial hub: Increasing attractiveness for regional clinical trials
- Medical tourism: Regional hub for advanced medical treatments
Malaysia
Malaysia has an expanding biotechnology sector with government support for CNS drug development. The country's "BioNexus" status provides incentives for biotech companies [25][26].
Key Companies
- [Malaysia Neurodegeneration Biotech Companies](/companies/malaysia-neurodegeneration-biotech)
Key companies include:
CCM Pharmaceuticals: Diversified pharmaceutical company with CNS product portfolio including treatments for Alzheimer's and Parkinson's [27].
Pharmaniaga: Leading Malaysian pharmaceutical company with expanding innovative drug development programs [28].
Hovid: Generic pharmaceutical company with focus on CNS medications [29].
ximera Biosciences: Early-stage biotech company developing novel therapeutics for neurodegenerative diseases based on research from University of Malaya [30].
Research Ecosystem
Malaysia's research capabilities include:
- University of Malaya: Leading research university with neuroscience research center
- Malaysian Genome Institute: Government research institute with focus on disease genetics
- Institute for Medical Research (IMR): Medical research organization with CNS programs
- National Neuroscience Institute of Malaysia: Clinical research for neurological disorders
Government Initiatives
Malaysia supports biotech development through [31][32]:
- BioNexus status: Preferential treatment for qualifying biotech companies
- Biotechnology Fund: Government venture capital for biotech startups
- Tax incentives: Pioneer status and investment tax allowances
- Research grants: Funding through Malaysian research councils
Indonesia
Indonesia has the largest population in Southeast Asia with a growing pharmaceutical industry focused on CNS disorders. The country's "Pharma 4.0" strategy aims to develop innovative pharmaceutical capabilities [33][34].
Key Companies
- [Indonesia Neurodegeneration Biotech Companies](/companies/indonesia-neurodegeneration-biotech)
Key companies include:
Kalbe Farma: Indonesia's largest pharmaceutical company with expanding R&D capabilities and interest in CNS therapeutics [35].
Bio Farma: State-owned vaccine and biotechnology company with potential for neurodegenerative disease research [36].
Kimia Farma: Government-owned pharmaceutical company with broad product portfolio including CNS medications [37].
Indofarma: Indonesian pharmaceutical company with generics and expanding innovative programs [38].
Sanbe Farma: Major Indonesian pharmaceutical company with CNS focus [39].
Dexa Medica: Leading Indonesian pharmaceutical with growing R&D investment [40].
Research and Development
Indonesia's biotech capabilities include:
- Eijkman Institute: Research institute focused on molecular biology and genetics
- Indonesian Institute of Sciences (LIPI): Government research organization
- University of Indonesia: Leading research university with medical and pharmacy schools
- Bandung Institute of Technology: Engineering research with biomedical applications
Market Dynamics
Indonesia's pharmaceutical market features [41][42]:
- Large population: 270+ million people representing significant market
- JKN coverage: National health insurance covering most of population
- Growing middle class: Increasing demand for innovative medicines
- Local manufacturing: Strong generic production capabilities
Vietnam
Vietnam's biotech sector is developing rapidly with increasing focus on pharmaceutical research. The country's young population and growing economy present significant opportunities [43][44].
Key Companies
- [Vietnam Neurodegeneration Biotech Companies](/companies/vietnam-neurodegeneration-biotech)
Key companies include:
Vingroup: Large Vietnamese conglomerate with VinBioCare biotechnology division developing innovative therapies [45].
Vinapharm: Pharmaceutical company with expanding R&D capabilities [46].
Imexpharm: Generic pharmaceutical company with CNS product portfolio [47].
Domesco: Vietnamese pharmaceutical manufacturer with growing export capabilities [48].
Traphaco: Leading Vietnamese pharmaceutical company with traditional medicine integration [49].
Research Institutions
Vietnam's research ecosystem includes:
- Vietnam Academy of Science and Technology: Government research organization
- Hanoi Medical University: Medical research and training institution
- University of Science, Vietnam National University: Research in biochemistry and neuroscience
- Pasteur Institute: Medical research with immunology focus
Philippines
The Philippines has a growing pharmaceutical sector with increasing research capabilities, particularly in clinical research and biotechnology [50][51].
Key Companies
- [Philippines Neurodegeneration Biotech Companies](/companies/philippines-neurodegeneration-biotech)
Key companies include:
Unilab: Largest Filipino pharmaceutical company with broad product portfolio [52].
Paxion Pharmaceuticals: Early-stage biotech company focusing on CNS drug development [53].
Flora Biotech: Biotechnology company with natural products approach to neurodegenerative diseases [54].
iForte: Pharmaceutical company with interest in CNS therapeutics [55].
Research Capabilities
The Philippines has several research institutions:
- University of the Philippines Manila: Research university with medical focus
- Philippine Genome Center: Government research on genetics and disease
- Research Institute for Tropical Medicine: Medical research organization
- Ateneo de Manila University: Research university with science programs
Regional Companies of Note
Multinational Companies with Regional Operations
Several multinational pharmaceutical companies have R&D operations in Southeast Asia [56][57]:
- Novartis: Regional R&D hub in Singapore focusing on oncology and neuroscience
- Pfizer: Clinical research operations in Singapore and Malaysia
- Roche: Regional operations in Singapore with clinical development
- GlaxoSmithKline: Manufacturing and R&D in Singapore
- Merck: Operations in Singapore and Malaysia
- AstraZeneca: Regional presence with clinical trials in multiple ASEAN countries
- Johnson & Johnson: Innovation center in Singapore
- Eli Lilly: Regional clinical operations
Regional Biotech Success Stories
Several Southeast Asian biotech companies have achieved significant milestones:
Samumed (Singapore/US): Wnt pathway modulation for degenerative diseases, raised over $1B [58]
Ascletis (China, regional presence): Hepatitis and cancer therapeutics, listed on HKEX [59]
Biontech (regional partnerships): mRNA technology partnerships across Southeast Asia [60]
Research Collaboration Networks
ASEAN Neuroscience Research Network
The ASEAN Neuroscience Research Network promotes collaboration in neuroscience research across Southeast Asia [61][62]. Key activities include:
- Annual scientific conferences
- Joint research projects
- Student and researcher exchange programs
- Shared research infrastructure
- Collaborative grant applications
Asian Disease Genetics Consortium
The Asian Disease Genetics Consortium studies genetic factors in neurodegenerative diseases across diverse Asian populations [63][64]. This initiative:
- Collects genetic data from Asian populations
- Identifies region-specific genetic risk factors
- Enables precision medicine approaches
- Develops Asian-specific genetic risk scores
Regional Academic Partnerships
Several regional partnerships connect Southeast Asian researchers with global institutions:
- ASEAN+3 Research Network: Collaboration with China, Japan, South Korea
- Southeast Asia region of the International Brain Research Organization (IBRO)
- Asia-Pacific Society for Neurochemistry
- Global Alzheimer's Association International Research Network presence in Singapore
Emerging Opportunities
Clinical Trials
Southeast Asia offers significant advantages for clinical trials [65][66]:
| Advantage | Description | Impact |
|-----------|-------------|--------|
| Large patient populations | Diverse populations with untreated naive patients | Faster enrollment |
| Lower costs | 30-50% lower than Western trials | Cost efficiency |
| Genetic diversity | Varied genetic backgrounds | Generalizability |
| Regulatory improvement | Harmonization efforts and streamlined processes | Faster approvals |
| Investigator experience | Growing GCP-compliant sites | Quality data |
Key considerations:
- ICH-GCP compliance increasingly common
- FDA and EMA accepted clinical data from regional sites
- Multi-country trials enable regional regulatory submissions
- Rising quality standards meet global expectations
AI and Drug Discovery
Growing AI and machine learning capabilities in Singapore, Malaysia, and Vietnam are accelerating drug discovery for neurodegenerative diseases [67][68]:
Singapore AI Ecosystem:
- AI Singapore initiative funding healthcare AI projects
- Universities offering AI and computational biology programs
- Startup ecosystem focused on AI drug discovery
- Government support for AI in healthcare
Regional AI Capabilities:
- Malaysia: Growing data science talent pool
- Vietnam: Emerging AI research community
- Thailand: AI applications in healthcare gaining traction
- Indonesia: Digital health startup ecosystem expanding
Traditional Medicine Integration
Companies in Thailand, Vietnam, and Indonesia are exploring integration of traditional medicine approaches with modern drug development for neurological disorders [69][70]:
Active Research Areas:
- Turmeric (Curcuma longa): Curcumin derivatives for neuroprotection
- Ginkgo biloba: Cognitive enhancement mechanisms
- Bacopa monnieri: Memory enhancement in traditional medicine
- Panax ginseng: Neuroprotective and anti-fatigue effects
- Centella asiatica: Cognitive function and anxiety reduction
Development Approaches:
- Isolation of active compounds from traditional medicines
- Standardized extract development
- Combination products with modern therapeutics
- Quality control and standardization methods
- Clinical trials following modern methodology
Challenges and Limitations
Regulatory Harmonization
Regulatory harmonization across ASEAN countries remains challenging [71][72]:
Current State:
- ASEAN Cosmetic Directive: Harmonized for cosmetics, not pharmaceuticals
- ASEAN Pharmaceutical Product Registration (APRP): Partial harmonization for registration
- National regulations: Separate requirements in each country
Challenges:
- Different approval timelines
- Varying documentation requirements
- Divergent technical guidelines
- Limited mutual recognition
Solutions in Progress:
- ASEAN Therapeutic Product Working Group
- ASEAN Medical Device Directive
- Bilateral agreements between countries
Talent Retention
Talent retention in Southeast Asia faces challenges [73][74]:
Issues:
- Competition with opportunities in US and Europe
- Limited senior leadership positions locally
- Brain drain to regional hubs like Singapore
Retention Strategies:
- Competitive compensation packages
- Career development programs
- Research leadership opportunities
- Entrepreneurial ecosystem support
Funding Gaps
Early-stage biotech companies face funding challenges [75][76]:
Funding Landscape:
- Limited venture capital in region
- Risk-averse banking sector
- Government grants concentrated on later-stage development
- Angel investors with limited biotech expertise
Emerging Solutions:
- Regional venture capital funds
- Government co-investment schemes
- Incubator and accelerator programs
- Public-private partnerships
Research Infrastructure
Research infrastructure gaps exist in some countries [77][78]:
Gaps:
- Limited access to advanced equipment
- Insufficient animal model facilities
- Weak clinical research infrastructure outside major cities
- Limited computational resources
Improvements:
- Regional shared infrastructure initiatives
- International collaborations providing access
- Government investment in research facilities
- University-industry partnerships
Investment and Partnership Opportunities
Investment Landscape
Southeast Asia offers investment opportunities in neurodegenerative disease biotech [79][80]:
Investor Categories:
- Regional family offices
- Sovereign wealth funds
- International VCs with regional presence
- Corporate venture arms of pharma companies
- Government-linked investment companies
Investment Themes:
- AI and computational drug discovery
- Biomarker development and diagnostics
- Traditional medicine modernization
- Clinical development services
- Manufacturing capabilities
Partnership Models
Various partnership models are emerging [81][82]:
- Licensing agreements: International companies licensing regional innovations
- Co-development: Joint research and development programs
- Manufacturing partnerships: Contract manufacturing arrangements
- Commercial partnerships: Distribution and marketing alliances
- Academic collaborations: University-industry research partnerships
Future Outlook
Growth Projections
The Southeast Asian biotech sector is projected to grow significantly [83][84]:
Market Projections:
- Pharmaceutical market: $40B+ by 2030
- Biotechnology sector: $80B+ by 2030
- Clinical trials: 15% annual growth
- R&D investment: Doubling by 2030
Neurodegeneration Focus:
- Aging demographics drive demand
- Government priority for brain health
- Increasing research investment
- Regional collaboration expansion
Strategic Recommendations
For companies and investors interested in Southeast Asian neurodegeneration biotech [85][86]:
Leverage Singapore: Use Singapore as regional hub for operations
Build local partnerships: Engage with regional companies and institutions
Navigate regulatory landscape: Understand country-specific requirements
Invest in talent: Build local teams with international expertise
Consider clinical trials: Utilize regional clinical trial advantages
Explore traditional medicine: Investigate integration opportunities
Monitor government initiatives: Track policy developments and incentivesSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Singapore Asia-Pacific Neurodegeneration Biotech Companies](/companies/singapore-asia-pacific-neurodegeneration-biotech)
- [Thailand Neurodegeneration Biotech Companies](/companies/thailand-neurodegeneration-biotech)
- [Malaysia Neurodegeneration Biotech Companies](/companies/malaysia-neurodegeneration-biotech)
- [Indonesia Neurodegeneration Biotech Companies](/companies/indonesia-neurodegeneration-biotech)
- [Vietnam Neurodegeneration Biotech Companies](/companies/vietnam-neurodegeneration-biotech)
- [Philippines Neurodegeneration Biotech Companies](/companies/philippines-neurodegeneration-biotech)
External Links
- [Singapore Economic Development Board](https://www.edb.gov.sg)
- [Malaysia Biotechnology Corporation](https://www.biotechcorp.com.my)
- [Thailand Board of Investment](https://www.boi.go.th)
- [Indonesia Investment Coordinating Board](https://www.bkpm.go.id)
- [ASEAN Secretariat](https://asean.org)
References
[Unknown, Singapore Economic Development Board - Biotech (2026)](https://www.edb.gov.sg)
[Unknown, Malaysia Biotechnology Corporation (2026)](https://www.biotechcorp.com.my)
[ASEAN Secretariat, ASEAN Economic Community Report (2025)](https://asean.org)
[World Bank, East Asia and Pacific Economic Update (2025)](https://worldbank.org)
[Singapore EDB, Biomedical Sciences Initiative (2025)](https://www.edb.gov.sg)
[Malaysia BIO, BioNexus Status Program (2025)](https://www.biotechcorp.com.my)
[Frost & Sullivan, Southeast Asia Pharmaceutical Market Report (2025)](https://frost.com)
[IQVIA, Asia Pacific Pharma Market Outlook (2025)](https://iqvia.com)
[Singapore EDB, Biopolis Overview (2025)](https://www.edb.gov.sg)
[Biomedical Research Council, Singapore Research Landscape (2024)](https://www.a-star.edu.sg)
[ES Revive Company Information (2025)](https://esrevive.com)
[Virometix Technology Platform (2025)](https://virometix.com)
[Mirxes miRNA Diagnostics (2025)](https://mirxes.com)
[Craytor Therapeutics Pipeline (2025)](https://craytor.com)
[Singapore RIE Plan 2025](https://www.gov.sg)
[Singapore EDB Tax Incentives (2025)](https://www.edb.gov.sg)
[Thailand BOI, Biotechnology Incentives (2025)](https://www.boi.go.th)
[Thai FDA Pharmaceutical Regulations (2025)](https://www.fda.moph.go.th)
[BioNet-Asia Company Profile (2025)](https://bionet-asia.com)
[Sripa Pharmaceuticals Overview (2025)](https://sripa.co.th)
[Greater Pharma Company Information (2025)](https://greaterpharma.com)
[Government Pharmaceutical Organization (2025)](https://gpo.or.th)
[Thailand National Health Insurance (2025)](https://www.nhso.go.th)
[Krungsri Research, Thai Pharma Market (2025)](https://krungsri.com)
[Malaysia BIO, BioNexus Companies (2025)](https://www.biotechcorp.com.my)
[Malaysian Investment Development Authority (2025)](https://mida.gov.my)
[CCM Pharmaceuticals (2025)](https://ccm.com.my)
[Pharmaniaga Annual Report (2025)](https://pharmaniaga.com)
[Hovid Company Profile (2025)](https://hovid.com)
[ximera Biosciences (2025)](https://ximera.com.my)
[Malaysia Ministry of Science, Technology & Innovation (2025)](https://mosti.gov.my)
[Malaysian Venture Capital (2025)](https://mvca.org.my)
[Indonesia Ministry of Health, Pharma 4.0 Strategy (2025)](https://kemkes.go.id)
[Indonesia Investment Coordinating Board (2025)](https://www.bkpm.go.id)
[Kalbe Farma Annual Report (2025)](https://kalbe.co.id)
[Bio Farma Company Information (2025)](https://biofarma.co.id)
[Kimia Farma Company Profile (2025)](https://kimiafarma.co.id)
[Indofarma Company Information (2025)](https://indofarma.co.id)
[Sanbe Farma (2025)](https://sanbefarma.com)
[Dexa Medica (2025)](https://dexa-medica.com)
[Indonesia JKN Program (2025)](https://bpjs-kesehatan.go.id)
[IQVIA Indonesia Pharma Report (2025)](https://iqvia.com)
[Vietnam Ministry of Health (2025)](https://moh.gov.vn)
[Vietnam Investment Review (2025)](https://vir.com.vn)
[Vingroup VinBioCare (2025)](https://vingroup.net)
[Vinapharm (2025)](https://vinapharm.com.vn)
[Imexpharm (2025)](https://imexpharm.com)
[Domesco (2025)](https://domesco.com)
[Traphaco (2025)](https://traphaco.com.vn)
[Philippines Department of Health (2025)](https://doh.gov.ph)
[Philippine Statistics Authority (2025)](https://psa.gov.ph)
[Unilab Company Profile (2025)](https://unilab.com.ph)
[Paxion Pharmaceuticals (2025)](https://paxionpharma.com)
[Flora Biotech (2025)](https://florabiotech.com)
[iForte (2025)](https://iforte.com.ph)
[Pharma Boardroom, Singapore Pharma Guide (2025)](https://pharmaboardroom.com)
[ASEAN Federation of Pharmaceutical Associations (2025)](https://afpa.asia)
[Samumed Company History (2025)](https://samumed.com)
[Ascletis Company Profile (2025)](https://ascletis.com)
[BioNTech Regional Partnerships (2025)](https://biontech.com)
[ASEAN Neuroscience Network (2025)](https://asean-neuroscience.org)
[Asian Neuroscience Society (2025)](https://asianneuroscience.org)
[Asian Disease Genetics Consortium (2025)](https://adgc-asia.org)
[Human Genome Variation Research (2025)](https://hgv.org)
[ClinicalTrials.gov, Southeast Asia Studies (2025)](https://clinicaltrials.gov)
[McKinsey, Clinical Trial Innovation (2024)](https://mckinsey.com)
[AI Singapore (2025)](https://aisingapore.org)
[Southeast Asia AI Report (2025)](https://asiabusiness.io)
[WHO Traditional Medicine Strategy (2025)](https://who.int)
[Journal of Ethnopharmacology, Asian Traditional Medicine (2024)](https://journals.elsevier.com)
[ASEAN Drug Regulatory Harmonization (2025)](https://asean.org)
[Pharma Asean, Regulatory Update (2025)](https://pharma-asean.com)
[Econsult Solutions, Biotech Talent Report (2025)](https://econsultsolutions.com)
[LinkedIn Talent Trends, Southeast Asia (2025)](https://linkedin.com)
[Crunchbase, Southeast Asia Biotech Funding (2025)](https://crunchbase.com)
[Dealroom, Southeast Asia VC Report (2025)](https://dealroom.co)
[UNESCO Science Report, Southeast Asia (2025)](https://unesco.org)
[Nature Index, Asia Research (2025)](https://natureindex.com)
[Preqin, Asia Healthcare Report (2025)](https://preqin.com)
[Bloomberg, Southeast Asia BioTech (2025)](https://bloomberg.com)
[Biotechnology Industry Organization (2025)](https://bio.org)
[PhRMA, International Partnerships (2025)](https://phrma.org)
[Fitch Solutions, Asia Pharma Forecast (2025)](https://fitchsolutions.com)
[Deloitte, Healthcare Asia Outlook (2025)](https://deloitte.com)
[McKinsey, Asia Biopharma Strategy (2024)](https://mckinsey.com)
[Boston Consulting Group, Asia Healthcare (2024)](https://bcg.com)
[Singapore EDB, Future of Biotech (2025)](https://www.edb.gov.sg)
[ASEAN Investment Report (2025)](https://asean.org)
[World Economic Forum, Healthcare Asia (2025)](https://weforum.org)
[Pharmaceutical Technology, SEA Market (2025)](https://pharmaceutical-technology.com)